Prevention of venous thrombosis and pulmonary embolism.
Deep vein thrombosis (DVT) leads to hospitalization for up to 600,000 persons each year in the United States. Venous thrombosis in itself may be benign, but the condition can lead to dangerous complications and has a high recurrence rate. Strategies to prevent DVT involve prevention of stasis and reversal of changes in blood coagulability that allow thrombi to form. Pharmacologic agents have been effective in reducing the incidence of DVT and pulmonary embolism. Low-dose subcutaneous heparin is considered a nearly ideal DVT preventative for surgically treated patients. The risk of hemorrhage is the main limitation to routine use of subcutaneous anticoagulants for DVT, but careful patient selection can minimize that risk. After anticoagulant therapy with heparin, generally for 7 to 10 days, oral warfarin is the drug of choice for maintenance anticoagulation to prevent DVT recurrence. Therapy for pulmonary embolism is the same as for DVT--immediate anticoagulation with heparin followed by maintenance with warfarin.
Kakkar
V
V
Thrombosis Research Unit, King's College School of Medicine and Dentistry, London, England.
D000925:Anticoagulants / Q000627:therapeutic use; D006493:Heparin / Q000627:therapeutic use; D006801:Humans; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use; D011655:Pulmonary Embolism / Q000517:prevention & control*; D013924:Thrombophlebitis / Q000517:prevention & control*
D000925:Anticoagulants; D010975:Platelet Aggregation Inhibitors; D006493:Heparin